Stenocare is exiting production activities at its Danish cultivation facility to focus on sales of finished medical cannabis products, that are already approved for sale, as well as the introduction of its new patented medical cannabis oil product, Astrum.
The company has determined that due to the timeline and the funding required, the likelihood of reaching breakeven for the facility is beyond its capabilities. The agreement to exchange the facility with Hedemann Løvstad Ejendomsselskab ApS is conditional upon the company's success in raising capital as announced October 14, 2024.
For more information:
STENOCARE A/S
[email protected]
stenocare.dk